Drug General Information
Drug ID	D0S9IE
Former ID	DIB001571
Drug Name	BAY1125976
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[524391]
Company	Bayer healthcare pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	AKT3 protein kinase	Target Info	Modulator	[1572591]
KEGG Pathway	MAPK signaling pathway
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Chemokine signaling pathway
	HIF-1 signaling pathway
	FoxO signaling pathway
	Sphingolipid signaling pathway
	mTOR signaling pathway
	PI3K-Akt signaling pathway
	AMPK signaling pathway
	Apoptosis
	Adrenergic signaling in cardiomyocytes
	VEGF signaling pathway
	Osteoclast differentiation
	Focal adhesion
	Tight junction
	Signaling pathways regulating pluripotency of stem cells
	Platelet activation
	Toll-like receptor signaling pathway
	Jak-STAT signaling pathway
	T cell receptor signaling pathway
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Fc gamma R-mediated phagocytosis
	TNF signaling pathway
	Neurotrophin signaling pathway
	Cholinergic synapse
	Dopaminergic synapse
	Insulin signaling pathway
	Progesterone-mediated oocyte maturation
	Estrogen signaling pathway
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Adipocytokine signaling pathway
	Glucagon signaling pathway
	Regulation of lipolysis in adipocytes
	Non-alcoholic fatty liver disease (NAFLD)
	Carbohydrate digestion and absorption
	Chagas disease (American trypanosomiasis)
	Toxoplasmosis
	Tuberculosis
	Hepatitis C
	Hepatitis B
	Measles
	Influenza A
	HTLV-I infection
	Epstein-Barr virus infection
	Pathways in cancer
	Proteoglycans in cancer
	Colorectal cancer
	Renal cell carcinoma
	Pancreatic cancer
	Endometrial cancer
	Glioma
	Prostate cancer
	Melanoma
	Chronic myeloid leukemia
	Acute myeloid leukemia
	Small cell lung cancer
	Non-small cell lung cancer
	Central carbon metabolism in cancer
Choline metabolism in cancer
NetPath Pathway	TSH Signaling Pathway
	IL2 Signaling Pathway
PANTHER Pathway	Angiogenesis
	Apoptosis signaling pathway
	EGF receptor signaling pathway
	Endothelin signaling pathway
	FGF signaling pathway
	Huntington disease
	Hypoxia response via HIF activation
	Inflammation mediated by chemokine and cytokine signaling pathway
	Interleukin signaling pathway
	PI3 kinase pathway
	T cell activation
	p53 pathway
	Ras Pathway
	p53 pathway by glucose deprivation
	p53 pathway feedback loops 2
Pathway Interaction Database	S1P3 pathway
	Class I PI3K signaling events mediated by Akt
References
Ref 524391	ClinicalTrials.gov (NCT01915576) Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients. U.S. National Institutes of Health.
Ref 1572591	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.